Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases

Table 1 General characteristics of non-small cell lung cancer patients with brain metastases in the concurrent immune checkpoint inhibitor group and consolidation immune checkpoint inhibitor group, n (%)

Characteristic	Concurrent ICI, N = 54	Consolidation ICI, N = 62	P value
Age, years			0.536
≤ 65	17 (31.5)	26 (41.9)
> 65	37 (68.5)	36 (58.1)
Sex			0.492
Male	33 (61.1)	34 (54.8)
Female	21 (38.9)	28 (45.2)
ECOG			0.735
0-1	12 (22.2)	17 (27.4)
2	42 (77.8)	45 (72.6)
Smoking			0.598
Yes	36 (66.7)	27 (43.5)
No	18 (33.3)	35 (56.5)
Histology			0.727
Squamous cell carcinoma	9 (16.7)	14 (22.6)
Adenocarcinoma	40 (74.1)	45 (72.6)
Other types	5 (9.3)	3 (4.8)
Tumor proportion score, %			0.712
≤ 1	19 (35.2)	20 (32.3)
1-49	8 (14.8)	6 (9.7)
≥ 50	15 (27.8)	22 (35.4)
Unknown	12 (22.2)	14 (22.6)
Number of brain metastases			0.421
≤ 3	43 (79.6)	44 (71.0)
> 3	11 (20.4)	18 (29.0)
Tumor diameters, mm			0.335
≤ 20	38 (70.4)	47 (75.8)
> 20	16 (29.6)	15 (24.2)
KRAS mutation			0.256
Positive	5 (9.3)	9 (14.5)
Wild type	49 (90.7)	53 (85.5)
TP53 mutation			0.398
Positive	7 (13.0)	8 (12.9)
Wild type	47 (87.0)	54 (87.1)
First line therapy			0.864
Yes	38 (70.4)	46 (74.2)
No	16 (29.6)	16 (25.8)
Extracranial metastases			0.710
Yes	33 (61.1)	35 (56.5)
No	21 (38.9)	27 (43.5)

ECOG: Eastern Cooperative Oncology Group; KRAS: Kirsten rat sarcoma viral oncogene; TP53: Tumor protein 53; ICI: Immune checkpoint inhibitor.